Serina Therapeutics Inc (SER)

$2.22 -0.28 (-11.20%)
Market Cap 56.39M
Revenue (ttm) 130,000.00
Net Income (ttm) -19.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14,753.85%
Debt to Equity Ratio 0.16
Volume 69,300
Avg Vol 55,606
Day's Range N/A - N/A
Shares Out 25.40M
Stochastic %K 3%
Beta 1.18
Analysts Strong Sell
Price Target $11.33

Company Profile

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has c...

Industry: Biotechnology
Sector: Healthcare
Phone: 256 327 9630
Address:
601 Genome Way, Suite 2001, Huntsville, United States
gamgee11
gamgee11 Sep. 9 at 3:50 PM
$SER guessing paid pumpers are on the way. Pump price for company to dilute
0 · Reply
jheerdink
jheerdink Sep. 9 at 2:47 PM
$SER gg
0 · Reply
prismmarketview
prismmarketview Sep. 9 at 2:17 PM
$SER — SER-252 (long-acting injectable apomorphine, POZ Platform) advances to Cohort 2 after independent Safety Monitoring Committee review of blinded Cohort 1 data (n=8, 3:1 randomized vs placebo). Blinded PK signal consistent with prolonged apomorphine exposure; some patients showed improved motor function on exploratory measures, not yet attributable to drug vs placebo. Full SAD study: 5 cohorts, 40 patients total, US/Australia/South Korea/Taiwan. Topline H1 2027. $SER #Biotech #Parkinsons https://prismmarketview.com/serina-moves-ser-252-into-second-dose-cohort-for-advanced-parkinsons-disease/
0 · Reply
gamgee11
gamgee11 Sep. 9 at 2:04 PM
$SER looks like a little more activity with post this morning. Pumpers might be about to post much more
0 · Reply
gamgee11
gamgee11 Sep. 9 at 2:03 PM
$SER more volume today. Nasty 5 min candle at open
0 · Reply
jheerdink
jheerdink Sep. 9 at 1:01 PM
$SER "Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received the green light to advance SER-252 into Cohort 2,..." https://vistapglobal.com/serina-therapeutics-clears-a-key-parkinsons-hurdle-pfe-ser-xbi/
0 · Reply
dthekang
dthekang Sep. 9 at 1:01 PM
$SER 🙏
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 9 at 12:32 PM
$SER Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
1 · Reply
jheerdink
jheerdink Sep. 9 at 4:22 AM
$SER "Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully easier to live with...." https://vistapglobal.com/serina-therapeutics-a-parkinsons-story-where-better-drug-delivery-could-become-the-main-event-pfe-ser-xbi/
0 · Reply
jheerdink
jheerdink Sep. 8 at 11:59 AM
$SER
0 · Reply
Latest News on SER
Serina Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 11, 2026, 7:00 AM EDT - 2 days ago

Serina Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 4:05 PM EDT - 2 days ago

Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Serina Therapeutics Slides: Investor presentation

Sep 10, 2026, 7:00 AM EDT - 3 days ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

Sep 9, 2026, 7:45 AM EDT - 4 days ago

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2

Serina Therapeutics files to sell 12.5M shares of common stock for holders

2026-08-24T21:30:14.000Z - 19 days ago

Serina Therapeutics files to sell 12.5M shares of common stock for holders

Serina Therapeutics Registration statement: Registration filing

Aug 24, 2026, 8:00 AM EDT - 20 days ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 13, 2026, 4:15 PM EDT - 4 weeks ago

Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

Serina Therapeutics Quarterly report: Q2 2026

Serina Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 4 weeks ago

Serina Therapeutics Earnings release: Q2 2026

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2026, 6:00 AM EDT - 7 weeks ago

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Serina Therapeutics completes enrollment and dosing in Parkinson’s trial

2026-07-23T10:20:24.000Z - 7 weeks ago

Serina Therapeutics completes enrollment and dosing in Parkinson’s trial

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

Jul 23, 2026, 6:00 AM EDT - 7 weeks ago

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board

2026-07-22T21:20:52.000Z - 7 weeks ago

Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board

TRVI

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Jul 22, 2026, 4:30 PM EDT - 7 weeks ago

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252

2026-07-09T16:15:10.000Z - 2 months ago

Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Jul 9, 2026, 12:10 PM EDT - 2 months ago

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Slides: Investor presentation

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics initiated with a Buy at BTIG

2026-07-01T09:30:10.000Z - 2 months ago

Serina Therapeutics initiated with a Buy at BTIG

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Jun 30, 2026, 9:01 AM EDT - 2 months ago

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Serina Therapeutics Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 2 months ago

Serina Therapeutics Transcript: AGM 2026

Serina Therapeutics files to sell 16.45M shares of common stock for holders

2026-05-22T20:06:20.000Z - 3 months ago

Serina Therapeutics files to sell 16.45M shares of common stock for holders

Serina Therapeutics Registration statement: Registration filing

May 22, 2026, 8:00 AM EDT - 3 months ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 14, 2026, 4:20 PM EDT - 4 months ago

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Serina Therapeutics Quarterly report: Q1 2026

Serina Therapeutics Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 4 months ago

Serina Therapeutics Earnings release: Q1 2026

Serina Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Apr 7, 2026, 6:00 AM EDT - 5 months ago

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

2026-04-02T20:21:42.000Z - 5 months ago

Serina Therapeutics announces NYSE acceptance of plan to regain compliance

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Apr 2, 2026, 4:13 PM EDT - 5 months ago

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

Serina Therapeutics Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Serina Therapeutics Annual report: Q4 2025

Serina Therapeutics Earnings release: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Serina Therapeutics Earnings release: Q4 2025

Serina Therapeutics Transcript: 38th Annual Roth Conference

Mar 24, 2026, 3:30 PM EDT - 5 months ago

Serina Therapeutics Transcript: 38th Annual Roth Conference

Serina Therapeutics to Present at the 38th Annual Roth Conference

Mar 24, 2026, 6:00 AM EDT - 5 months ago

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics names Greg Bailey co-chairman

2026-03-18T20:30:41.000Z - 5 months ago

Serina Therapeutics names Greg Bailey co-chairman

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Mar 18, 2026, 4:10 PM EDT - 5 months ago

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics Slides: Investor presentation

Mar 16, 2026, 8:00 AM EDT - 6 months ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics doses first patient in SER-252 trial

2026-02-24T21:37:35.000Z - 6 months ago

Serina Therapeutics doses first patient in SER-252 trial

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 24, 2026, 4:05 PM EST - 6 months ago

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

2026-02-19T11:20:45.000Z - 6 months ago

Serina Therapeutics says first patient enrolled in Phase 1b trial of SER-252

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Feb 19, 2026, 6:00 AM EST - 6 months ago

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Feb 3, 2026, 6:00 AM EST - 7 months ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event

Serina Therapeutics files to sell 7.72M shares of common stock for holders

2026-01-30T22:25:13.000Z - 7 months ago

Serina Therapeutics files to sell 7.72M shares of common stock for holders

Serina Therapeutics Registration statement: Registration filing

Jan 30, 2026, 7:00 AM EST - 7 months ago

Serina Therapeutics Registration statement: Registration filing

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

2026-01-29T14:53:03.000Z - 7 months ago

This Is Why Serina Therapeutics Stock (SER) Rocketed Today

Serina Therapeutics announces FDA clearance of SER-252 new drug application

2026-01-28T21:31:30.000Z - 7 months ago

Serina Therapeutics announces FDA clearance of SER-252 new drug application

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Jan 28, 2026, 4:12 PM EST - 7 months ago

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease

Serina Therapeutics receives NYSE deficiency notice on equity standards

2026-01-15T21:40:23.000Z - 8 months ago

Serina Therapeutics receives NYSE deficiency notice on equity standards

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Jan 15, 2026, 4:30 PM EST - 8 months ago

Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Dec 11, 2025, 4:15 PM EST - 9 months ago

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Serina Therapeutics submits complete response to FDA clinical hold letter

2025-12-10T21:45:32.000Z - 9 months ago

Serina Therapeutics submits complete response to FDA clinical hold letter

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Dec 10, 2025, 4:30 PM EST - 9 months ago

Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program

Serina Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Serina Therapeutics Quarterly report: Q3 2025

Serina Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 10 months ago

Serina Therapeutics Earnings release: Q3 2025

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

2025-11-13T11:15:52.000Z - 10 months ago

Serina Therapeutics reports Q3 EPS (45c) vs. 13c last year

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 13, 2025, 6:10 AM EST - 10 months ago

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics says FDA places clinical hold on IND for SER-252

2025-11-03T11:16:17.000Z - 10 months ago

Serina Therapeutics says FDA places clinical hold on IND for SER-252

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Nov 3, 2025, 6:05 AM EST - 10 months ago

Serina Therapeutics Provides Regulatory Update on SER-252 Program

Serina Therapeutics Proxy statement: Proxy filing

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Oct 8, 2025, 11:00 AM EDT - 11 months ago

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Oct 6, 2025, 4:15 PM EDT - 11 months ago

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics Proxy statement: Proxy filing

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Sep 26, 2025, 8:00 AM EDT - 11 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Proxy statement: Proxy filing

Sep 15, 2025, 8:00 AM EDT - 12 months ago

Serina Therapeutics Proxy statement: Proxy filing

Serina Therapeutics Inc trading resumes

2025-09-09T20:00:41.000Z - 1 year ago

Serina Therapeutics Inc trading resumes

Serina Therapeutics announces agreement to access up to $20M in financing

2025-09-09T19:30:14.000Z - 1 year ago

Serina Therapeutics announces agreement to access up to $20M in financing

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Sep 9, 2025, 3:20 PM EDT - 1 year ago

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Aug 25, 2025, 4:15 PM EDT - 1 year ago

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 11, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Earnings release: Q2 2025

Serina Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Quarterly report: Q2 2025

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Jul 29, 2025, 6:44 AM EDT - 1 year ago

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Jul 10, 2025, 4:10 PM EDT - 1 year ago

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Jul 1, 2025, 4:15 PM EDT - 1 year ago

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

Jun 23, 2025, 7:24 PM EDT - 1 year ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 8:30 PM EDT - 1 year ago

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Jun 9, 2025, 4:05 PM EDT - 1 year ago

Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

May 22, 2025, 4:50 PM EDT - 1 year ago

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

May 14, 2025, 3:15 PM EDT - 1 year ago

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 8, 2025, 4:23 PM EDT - 1 year ago

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Earnings release: Q1 2025

Serina Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Quarterly report: Q1 2025

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics Registration statement: Registration filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Slides: Investor presentation

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Apr 15, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Apr 8, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Apr 7, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Registration statement: Registration filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Registration statement: Registration filing

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Mar 24, 2025, 4:30 PM EDT - 1 year ago

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics Annual report: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Annual report: Q4 2024

Serina Therapeutics Earnings release: Q4 2024

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Earnings release: Q4 2024

Serina Therapeutics Slides: Investor presentation

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Mar 24, 2025, 6:30 AM EDT - 1 year ago

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Feb 12, 2025, 4:15 PM EST - 1 year ago

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Feb 3, 2025, 4:30 PM EST - 1 year ago

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Jan 15, 2025, 4:05 PM EST - 1 year ago

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Jan 14, 2025, 5:25 PM EST - 1 year ago

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics Slides: Investor presentation

Jan 6, 2025, 7:00 AM EST - 1 year ago

Serina Therapeutics Slides: Investor presentation

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Dec 16, 2024, 6:00 AM EST - 1 year ago

Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

gamgee11
gamgee11 Sep. 9 at 3:50 PM
$SER guessing paid pumpers are on the way. Pump price for company to dilute
0 · Reply
jheerdink
jheerdink Sep. 9 at 2:47 PM
$SER gg
0 · Reply
prismmarketview
prismmarketview Sep. 9 at 2:17 PM
$SER — SER-252 (long-acting injectable apomorphine, POZ Platform) advances to Cohort 2 after independent Safety Monitoring Committee review of blinded Cohort 1 data (n=8, 3:1 randomized vs placebo). Blinded PK signal consistent with prolonged apomorphine exposure; some patients showed improved motor function on exploratory measures, not yet attributable to drug vs placebo. Full SAD study: 5 cohorts, 40 patients total, US/Australia/South Korea/Taiwan. Topline H1 2027. $SER #Biotech #Parkinsons https://prismmarketview.com/serina-moves-ser-252-into-second-dose-cohort-for-advanced-parkinsons-disease/
0 · Reply
gamgee11
gamgee11 Sep. 9 at 2:04 PM
$SER looks like a little more activity with post this morning. Pumpers might be about to post much more
0 · Reply
gamgee11
gamgee11 Sep. 9 at 2:03 PM
$SER more volume today. Nasty 5 min candle at open
0 · Reply
jheerdink
jheerdink Sep. 9 at 1:01 PM
$SER "Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received the green light to advance SER-252 into Cohort 2,..." https://vistapglobal.com/serina-therapeutics-clears-a-key-parkinsons-hurdle-pfe-ser-xbi/
0 · Reply
dthekang
dthekang Sep. 9 at 1:01 PM
$SER 🙏
0 · Reply
Stock_Catcher
Stock_Catcher Sep. 9 at 12:32 PM
$SER Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
1 · Reply
jheerdink
jheerdink Sep. 9 at 4:22 AM
$SER "Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully easier to live with...." https://vistapglobal.com/serina-therapeutics-a-parkinsons-story-where-better-drug-delivery-could-become-the-main-event-pfe-ser-xbi/
0 · Reply
jheerdink
jheerdink Sep. 8 at 11:59 AM
$SER
0 · Reply
dthekang
dthekang Sep. 4 at 4:25 AM
$SER patiently waiting.
0 · Reply
AC_TRADER
AC_TRADER Aug. 18 at 7:18 PM
$SER some upside levels being hit. +17% since some lines have been drawn.
0 · Reply
PeePeePantsCity
PeePeePantsCity Aug. 14 at 1:26 AM
$SER Wow, $130,000 this quarter🤣🤣🤣I'm out!
0 · Reply
littleimagination
littleimagination Aug. 11 at 2:29 PM
$SER Insiders been buying Serina, Great sign!
0 · Reply
dthekang
dthekang Aug. 11 at 5:38 AM
$SER 🔥🫡
0 · Reply
robiein35
robiein35 Aug. 10 at 7:22 PM
$SER something big in making . Slow accumulation to avoid short attack.
0 · Reply
Rampageusa
Rampageusa Aug. 7 at 11:36 AM
$SER watch list 11% pop..more to come 5++
0 · Reply
gamgee11
gamgee11 Aug. 6 at 9:50 PM
$SER
1 · Reply
AC_TRADER
AC_TRADER Aug. 6 at 7:48 PM
$SER Levels made with @TrendSpider https://share.trendspider.com/chart/SER/7594hxhvdf
0 · Reply
dthekang
dthekang Aug. 5 at 11:44 AM
$SER 🔥
0 · Reply
robiein35
robiein35 Jul. 23 at 3:39 PM
$SER https://www.globenewswire.com/news-release/2026/07/23/3331950/0/en/Serina-Therapeutics-Announces-Completion-of-Enrollment-and-Dosing-in-Cohort-1-of-Registrational-Trial-of-SER-252-for-Advanced-Parkinson-s-Disease.html
0 · Reply
littleimagination
littleimagination Jul. 23 at 2:55 PM
$SER This company merged with AGEX years ago, so it looks to me like we have 2 excellent companies rolled into one. I like that I see Insider buying with serina. thats a rarity these days. According to my due diligence. Companies like Serina have the potential to generate billions with coordinated therapies for these diseases. They don't even have to cure anything. It's all in the delivery system. So, hypothetically, if J&J ,Pfe, or Mrk wants to buy Serina for $50 a share. That's a win too.
0 · Reply